Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 22;7:12150. doi: 10.1038/s41598-017-12257-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Random forest and biochemical analysis detect cross-stimulation of Met by EGFR following ligand exposure. (a) Random forest classification of non-linear combinations of features that reflect molecular interactions between receptors. Feature importance was calculated by repeatedly generating random forests from sub-samples of the data. (b) Biochemical analysis of Met-EGFR interaction. Serum-starved BT20 cells were pre-treated for 15 min with 1 µM Gefitinib for EGFR or SU11274 for Met or DMSO as a control and then stimulated for 5 min with EGF (which binds EGFR) and/or HGF (which binds Met) or medium as a control. Receptor immunoprecipitates were subjected to SDS-PAGE and immunoblots were probed with an anti-phospho-tyrosine antibody, anti-EGFR or anti-Met antibodies and respective secondary antibodies. The full length blots are presented in Supplementary Fig. 8. (c) Background-subtracted phospho-Met signals were corrected for total Met expression, normalized to the EGF/HGF-treated sample and plotted as mean with standard deviation derived from three biological replicates.